Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.

Khosrow-Khavar, Farzin; Desai, Rishi J; Lee, Hemin; Lee, Su Been; Kim, Seoyoung C

Khosrow-Khavar, Farzin; Desai, Rishi J; Lee, Hemin; Lee, Su Been; Kim, Seoyoung C.

Afiliação

Khosrow-Khavar F; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Desai RJ; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Lee H; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Lee SB; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.
Kim SC; Division of Pharmacoepidemiology and Pharmacoeconomics, and Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.

Arthritis Rheumatol ; 74(10): 1648-1659, 2022 10.

Article em En | MEDLINE | ID: mdl-35643956

Assuntos

Antirreumáticos; Artrite Reumatoide; Neoplasias; Antirreumáticos/efeitos adversos; Artrite Reumatoide/epidemiologia; Humanos; Neoplasias/induzido quimicamente; Neoplasias/tratamento farmacológico; Neoplasias/epidemiologia; Piperidinas; Pirimidinas; Inibidores do Fator de Necrose Tumoral

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Artrite Reumatoide / Antirreumáticos / Neoplasias Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Arthritis Rheumatol Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google